Table 4 Treatment exposure and dose modifications
Lenalidomide | Ibrutinib | |||||
|---|---|---|---|---|---|---|
Dose K, N = 7 | Dose K-1, N = 6 | Overall, N = 13 | Dose K, N = 5 | Dose K + 1, N = 7 | Overall, N = 12 | |
Mean relative dose intensity, % (SD) Lenalidomide Ibrutinib Rituximab Methotrexate Procarbazine Vincristine | 77.2 (33) NA 98.5 (3.2) 82.8 (17.9) 83.8 (32.5) 61.6 (19.2) | 95.6 (12.3) NA 95.4 (6.1) 93.1 (6.5) 94.1 (9.9) 82.8 (27.5) | 85.7 (26.4) NA 97.1 (4.8) 87.5 (14.4) 88.5 (24.5) 71.4 (24.9) | NA 84.8 (7.1) 99.8 (1.2) 99.2 (0.9) 98 (8.1) 87.5 (28.0) | NA 92 (7.5) 99.1 (2.1) 97.1 (6.5) 104.4 (6.7) 90.5 (20.1) | NA 89 (7.9) 99.4 (1.8) 97.9 (4.9) 101.7 (7.7) 89.3 (22.5) |
Dose delay because of an AE, N (%) ≥ 3 days ≥ 7 days | 3 (42.9) 3 (42.9) | 4 (66.7) 3 (50) | 7 (53.8) 6 (46.2) | 2 (40) 1 (20) | 5 (71.4) 3 (42.9) | 7 (58.3) 4 (33.3) |
Dose reduction because of an AE, N (%) Lenalidomide Ibrutinib Rituximab Methotrexate Procarbazine Vincristine | 3 (42.9) NA 0 (0) 4 (57.1) 1 (14.43) 6 (85.7) | 2 (33.3) NA 0 (0) 0 (0) 0 (0) 2 (33.3) | 5 (38.5) NA 0 (0) 4 (30.8) 1 (7.7) 8 (61.5) | NA 3 (60) 1 (20) 0 (0) 1 (20) 1 (20) | NA 3 (42.9) 0 (0) 1 (14.3) 0 (0) 2 (28.6) | NA 6 (50) 1 (8.3) 1 (8.3) 1 (8.3) 3 (25) |